HeberNasvac, a therapeutic vaccine for chronic hepatitis B, is able to safely stimulate multiple Toll-like receptors, increasing antigen presentation in vitro and in a phase II clinical trial (Profira) in elderly volunteers who were household contacts of respiratory infection patients. Thus, a new indication as a postexposure prophylaxis or early therapy for respiratory infections has been proposed. In this study, we evaluated the expression of several interferon-stimulated genes (ISGs) after mucosal administration of HeberNasvac and compared this effect with the nasal delivery of interferon alpha 2b (Nasalferon). Molecular studies of blood samples of 50 subjects from the Profira clinical trial who were locally treated with HeberNasvac or Nasalferon and concurrent untreated individuals were compared based on their relative mRNA expression of OAS1, ISG15, ISG20, STAT1, STAT3, and DRB1-HLA II genes. In most cases, the gene expression induced by HeberNasvac was similar in profile and intensity to the expression induced by Nasalferon and significantly superior to that observed in untreated controls. The immune stimulatory effect of HeberNasvac on ISGs paved the way for its future use as an innate immunity stimulator in elderly persons and immunocompromised subjects or as part of Mambisa, a nasal vaccine to prevent severe acute respiratory syndrome coronavirus 2 infection.
Get full access to this article
View all access options for this article.
References
1.
AguiarJ, SilvaJA, GellO, et al.An in house qPCR System to Evaluate Transcripts Stimulated by an Immune Innate Agonist (CIGB2020) during the Covid19 Pandemic Scenario. Appl Cell Biol, 2022a;10(2):45–50; doi: 10.53043/2320-1991.acb90024
2.
AguiarJ, FleitesY, CinzaZ, et al.Stimulation of TLRs gene expression detected by two different PCR methodologies in oropharyngeal scraping after mucosal application of HeberNasvac (CIGB2020) vaccine. Biotecnol Apl, 2022b (In Press).
3.
AguilarJC, AguiarJ, Van-De-Klun DertM, et al.Viral nucleoprotein and formulations thereof. Cuba patent application CU 2020-0028. 2020.
4.
AguilarJC, AguiarJ, AkbarSM. Action mechanisms and scientific rationale of using nasal vaccine (HeberNasvac) for the treatment of chronic hepatitis B. Vaccines, 2022; 10:2087; DOI.org/10.3390/vaccines10122087
5.
AguilarJC, LobainaY, MuzioV, et al.Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol, 2004; 82:539–546; doi: 10.1111/j.0818-9641.2004.01278.x
6.
AkbarSM, YoshidaO, ChenS, et al.Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface Ag and core antigen for treating chronic HBV infection. Antivir Ther, 2010; 15(6):887–895; doi: 10.3851/IMP1637
7.
AlecsandruD, ValorL, Sánchez-RamónS, et al.Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: Immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol, 2011; 164(1):100–107; doi: 10.1111/j.1365-2249.2011.04320.x
8.
Al-MahtabM, AkbarSM, AguilarJC, et al.Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int, 2013; 7(4):981–989; doi: 10.1007/s12072-013-9486-4
9.
Al MahtabM, AkbarSMF, AguilarJC, et al.Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One, 2018; 13(8):e0201236; doi: 10.1371/journal.pone.0201236
10.
BastardP, RosenLB, ZhangQ, et al.Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020; 370(6515):eabd4585; doi: 10.1126/science.abd4585
11.
CañeteR, LeónLM, RodriguezL. Experience with Cuban Biotech's Nasalferon to Prevent SARS-COV-2 infections in international travelers and their contacts. MEDICC Rev, 2021; 23(2):10; doi: 10.37757/MR2021.V23.N2.1
12.
CapraroA, WongS, AdhikariA, et al.Aging impairs the airway epithelium defence response to SARS-CoV-2. bioRxiv preprint, 2021; DOI: 10.1101/2021.04.05.437453
13.
CooperA, TalG, LiderO, et al.Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol, 2005; 175(5):3165–3176; doi: 10.4049/jimmunol.175.5.3165
14.
DegolsG, EldinP, MechtiN. ISG20, an actor of the innate immune response. Biochimie, 2007; 89(6–7):831–835; doi: 10.1016/j.biochi.2007.03.006
15.
De SpiegelaereW, Dern-WielochJ, WeigelR, et al.Reference gene validation for RT-qPCR, a note on different available software packages. PLoS One, 2015; 10 (3):e0122515; doi: 10.1371/journal.pone.0122515
16.
FengE, BalintE, PoznanskiS, et al.Aging and interferons: Impacts on inflammation and viral disease outcomes. Cells, 2021; 10(3):14–21; DOI.org/10.3390/cells10030708
17.
FleitesY, AguiarJ, CinzaZ, et al.Therapeutic vaccine for chronic hepatitis B, stimulates local and systemic markers of innate immunity: Potential use in SARS-CoV-2 postexposure prophylaxis. Eur J Hepato Gastroenterol, 2021; 11(2):59–70; doi: 10.5005/jp-journals-10018-1344
18.
HadjadjJ, YatimN, BarnabeiL, et al.Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. Science, 2020; 369(6504):718–724; doi: 10.1126/science.abc6027
19.
HilditchC, RogersL, BishopD. Physicochemical analysis of the Hepatitis B virus core antigen produced by baculovirus expression vector. J Gen Virol, 1990; 71(11):2755–2759; doi: 10.1099/0022-1317-71-11-2755
20.
HillmerEJ, ZhangH, LiHS, et al.STAT3 signaling in immunity. Cytokine Growth Factor Rev, 2016; 31:1–15.
21.
HuM, SuZ, YinY, et al.Calcineurin B subunit triggers innate immunity and acts as a novel Engerix-B® HBV vaccine adjuvant. Vaccine, 2012; 30(32):4719–4727; DOI.org/10.1016/j.vaccine.2012.05.040
22.
IvashkivLB. IFNγ: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol, 2018; 18(9):545–558; doi: 10.1038/s41577-018-0029-z
23.
KikkertM. Innate immune evasion by human respiratory RNA viruses. J Innate Immunity, 2020; 12(1):4–20; doi: 10.1159/000503030
24.
KristiansenH, SchererCA, McVeanM, et al.Extracellular 2′-5′ oligoadenylate synthetase stimulates RNase L-independent antiviral activity: A novel mechanism of virus-induced innate immunity. J Virol, 2010; 84(22):11898–11904; doi: 10.1128/JVI.01003-10
25.
KumakiY, SalazarAM, WanderseeMK, et al.Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC: LC), in a lethal SARS-CoV-infected BALB/c mouse model. Antiviral Res, 2017; 139:1–2; doi: 10.1016/j.antiviral.2016.12.007
26.
LangtonD, BourkeS, LieB, et al.The influence of HLA genotype on the severity of COVID-19 infection. HLA, 2021; 98(1):14–22; doi: 10.1111/tan.14284
27.
LaurellH, LacovoniJ, AbotA, et al.Correction of RT-qPCR data for genomic DNA-derived signals with ValidPrime. Nucleic Acid Res, 2012; 40(7):1–10. e51; doi: 10.1093/nar/gkr125915
28.
LeeBO, TuckerA, FrelinL, et al.Interaction of the hepatitis B core antigen and the innate immune system. J Immunol, 2009; 182(11):6670–6681; doi: 10.4049/jimmunol.0803683
29.
LiuY, NieH, MaoR, et al.Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog, 2017; 13(4):e1006296; doi: 10.1371/journal.ppat.1006296
30.
LobainaY, HardtkeS, WedemeyerH, et al.In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol, 2015; 63(2):320–327; doi: 10.1016/j.molimm.2014.08.003
31.
MetcalfTU, CubasRA, GhneimK, et al.Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell, 2015; 14(3):421–432; doi: 10.1111/acel.12320
32.
MullerP, JanovjakH, MiserezA, et al.Processing of gene expression data generated by quantitative real-time RT-PCR. BioComputing/BioInformatics Short Technical Report. BioTechniques, 2002; 32(6):1372–1374; PMID: 12074169
33.
Neumann-PodczaskaA, Al-SaadSR, KarbowskiLM, et al.COVID 19—Clinical picture in the elderly population: A qualitative systematic review. Aging Dis, 2020; 11(4):988–1008; doi: 10.14336/AD.2020.0620
34.
OkumuraF, OkumuraAJ, UematsuK, et al.Activation of double-stranded RNA-activated protein kinase (PKR) by interferon-stimulated gene 15 (ISG15) modification down-regulates protein translation. J Biol Chem, 2013; 288(4):2839–2847; doi: 10.1074/jbc.M112.401851
35.
PfafflMW.Quantification Strategies in Real-Time PCR. In: A-Z of Quantitative PCR (Bustin SA, ed.). International University Line (IUL): La Jolla, CA; 2004; pp. 87–112.
36.
PfafflMW.Relative Quantification. In: Real-Time PCR. (Dorak T, ed.) International University Line: New York, USA; 2006; pp. 63–82.
37.
PierangeliA, GentileM, OlivetoG, et al.Comparison by age of the local interferon response to SARS-CoV-2 suggests a role for IFN-ɛ and –ω. Front Immunol, 2022; 13:1–10; doi: 10.3389/fimmu.2022.873232
38.
RiedlP, StoberD, OehningerC, et al.Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol, 2002; 168(10):4951–4959; doi: 10.4049/jimmunol.168.10.4951
39.
RitchieKJ, ZhangDE. ISG15: The immunological kin of ubiquitin. Semin Cell Dev Biol, 2004; 15(2):237–246; doi: 10.1016/j.semcdb.2003.12.005
40.
Sánchez-RamónS, ConejeroL, NeteaMG, et al.Trained immunity-based vaccines: A new paradigm for the development of broad-spectrum anti-infectious formulations. Front Immunol, 2018; 9:2936; doi: 10.3389/fimmu.2018.02936
Sánchez-RamónS, Pérez de DiegoR, Dieli-CrimiR, et al.Extending the clinical horizons of mucosal bacterial vaccines: Current evidence and future prospects. Curr Drug Targets, 2014; 15(12):1132–1143; doi: 10.2174/1389450115666141020160705
43.
SariolCA, MartínezMI, RiveraF, et al.Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaques. PLoS One, 2011; 6(4):e19323; doi: 10.1371/journal.pone.0019323
44.
ShiraishiK, YoshidaO, ImaiY, et al.Intranasal HBsAg/HBcAg-containing vaccine induces neutralizing anti-HBs production in hepatitis B vaccine non-responders. Vaccines, 2023; 11:1479; DOI.org/10.3390/vaccines11091479
StadlerD, KächeleM, JonesAN, et al.Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep, 2021; 22(6):e49568; doi: 10.15252/embr.201949568
47.
TolomeoM, CavalliA, CascioA. STAT1 and its crucial role in the control of viral infections. Int J Mol Sci, 2022; 23(8):4095; doi: 10.3390/ijms23084095
48.
VabretN, BrittonGJ, GruberC, et al.Sinai immunology review project. Immunology of COVID-19: Current state of the science. Immunity, 2020; 52(6):910–941; doi: 10.1016/j.immuni.2020.05.002
49.
Vázquez-BlomquistD, Bequet-RomeroM, Mendoza-MaríY, et al.Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood. Clin Immunol Commun, 2022; 2:39–45; DOI: 10.1016/j.clicom.2022.02.002
50.
Vázquez-BlomquistD, FernándezJ, MirandaJ, et al.Gene expression profile in cervical carcinoma cells treated with HeberFERON. Bionatura, 2018; 3(4):702–708; doi: 10.21931/RB/2018.03.04.3
51.
WangN, ZhanY, ZhuL, et al.Retrospective multicenter cohort study shows that early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe, 2020; 28:455–464; DOI.org/10.1016/j.chom.2020.07.005
52.
WeissCM, TrobaughDW, SunC, et al.The interferon-induced exonuclease ISG20 exerts antiviral activity through upregulation of type I interferon response proteins. Msphere, 2018; 3(5):e00209–e00218; doi: 10.1128/mSphere.00209-18
53.
WooAS, KwokR, AhmedT. Alpha interferon treatment in hepatitis B. Ann Transl Med, 2017; 5(7):159; doi: 10.21037/atm.2017.03.69
54.
ZhaoJ, Wohlford-LenaneC, ZhaoJ, et al.Intranasal treatment with poly (I· C) protects aged mice from lethal respiratory virus infections. J Virol, 2012; 86(21):11416–11424; doi: 10.1128/JVI.01410-12
55.
ZhouZ, WangN, WoodsonSE, et al.Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology, 2011; 409(2):175–188; doi: 10.1016/j.virol.2010.10.008
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
